American CryoStem Announces Agreement With the nanoRANCH Division of UHV Technologies for Cancer Research Utilizing ATCELL(TM)

EATONTOWN, Jun 18, 2014 (GLOBE NEWSWIRE via COMTEX) American CryoStem Corporation (OTCQB:CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has entered into initial agreements with the nanoRANCH Division of UHV Technologies, Inc. ( nanoRANCH ) for the development of methods for the delivery of therapeutics and drugs focused upon cancer treatments utilizing adipose derived adult stem cells. The Company will be working with Dan Dimitrijevich, PhD to create new treatment delivery methods utilizing a combination of nanoRANCH unique technology and CRYO s clinically processed ATCELLs(TM). The Company s research collaboration into cancer research and cancer related applications utilizing CRYO s clinically processed ATCELL(TM) products further expands relationships and potential applications to treat a wide range of diseases in the
http://bit.ly/UM7F7d